Ozempic generic
Ozempic is an anti-diabetic drug that is manufactured and owned by Novo. The active ingredient in Ozempic is semaglutide. The drug was first authorized for market use on the 5th of December, 2017. Out of 25 drug patents owned by Ozempic, 4 patents have expired to date.
When will Ozempic generic be available?
The possibility of releasing generic versions of Ozempic is expected after the 21st of June, 2033. Determining the availability of a generic version of Ozempic is dependent upon the status of its patents. The patent that impacts the date of the generic release of Ozempic is patent US10335462 titled 'Use of long-acting GLP-1 peptides', which is due to expire on the 21st of June, 2033. Thus, the Ozempic generic will not be available until after this date.
Ozempic uses
Ozempic is primarily used to treat type 2 diabetes. It functions by consistently administering semaglutide once weekly in an amount of 1.0 mg to the patient. Ozempic is known to significantly improve glycemic control in adults when it is used as an adjunct to diet and exercise. Its effectiveness is mainly derived from the contribution of semaglutide, its active ingredient.
Ozempic patent expiration
Ozempic owns 25 drug patents with the last patent, US10335462 titled 'Use of long-acting GLP-1 peptides', set to expire on the 21st of June, 2033. The date of the expiration of this patent dictates the release of the Ozempic generic. Below are the details of the patent: